Rubnitz J E, Behm F G, Wichlan D, Ryan C, Sandlund J T, Ribeiro R C, Rivera G K, Hancock M L, Relling M V, Evans W E, Pui C H, Downing J R
Department of Hematology/Oncology, St Jude Children's Research Hospital, University of Tennessee College of Medicine, Memphis 38105-2794, USA.
Leukemia. 1999 Jan;13(1):19-21. doi: 10.1038/sj.leu.2401257.
The long-term outcome of children with TEL-AML1-positive acute lymphoblastic leukemia (ALL) is uncertain. Although studies of newly diagnosed cases have indicated that the TEL-AML1 fusion confers a favorable prognosis, analyses of relapsed cases have suggested that this may not be true. Because of treatment implications for this subgroup of patients, we have now analyzed 49 cases of relapsed ALL for the presence of TEL-AML1. Only 10% of these cases expressed the fusion, compared to 20-25% of newly diagnosed ALL cases. Additional follow-up of the cohort of 48 newly diagnosed patients with the TEL-AML1 fusion previously reported showed that the 10-year cumulative risk of relapse was 9 +/- 5% (s.e.). Together, these results suggest an excellent outcome for TEL-AML1-positive ALL.
